Lower GI 2017

CORS-03 study

EBRT boost n=33

N2/3 (iliac/inguinal LN) n= 32

BCT boost n=34

Macroscopic LN involvement n= 99

EBRT boost n=16

N1 (perirectal LN) n= 67

229 patients with anal carcinoma

BCT boost n=16

No LN involvement n= 130

CORS-3 study

BCT boost is superior to EBRT boost for local control , without an influence on OS  N1 status should not be a contraindication for a BCT boost technique

Laurence Moureau-Zabotto et al, IJROBP 2013

10